- The disease
- Erythropoietic protoporphyria (EPP) is a rare inherited condition in which a defect in haem biosynthesis causes abnormal accumulation of protoporphyrin IX, a compound that becomes toxic when activated by light. Patients experience severe burning pain in skin exposed to sunlight or artificial light, which can last hours to days. Because even brief light exposure triggers symptoms, most patients severely restrict their time outdoors. EPP is classified as an orphan disease due to its very low prevalence.
- What the asset is trying to do
- SCENESSE (afamelanotide) is a synthetic analogue of alpha-melanocyte stimulating hormone (alpha-MSH) that acts as an agonist at the melanocortin 1 receptor (MC1R). Activation of MC1R stimulates melanin production in skin, increasing the skin's natural pigmentation and its capacity to absorb light energy before it can activate accumulated protoporphyrin IX. The drug is delivered as a slow-release subcutaneous implant, providing sustained plasma levels. This mechanism differs from supportive measures such as physical sun protection, which act as external barriers rather than modifying skin biology.
- What the trial is measuring, and why it matters
- The recently completed pharmacokinetics study (NCT06388642) measured how the body absorbs, distributes, and eliminates afamelanotide in EPP patients, with a target enrolment of 28 participants (per ClinicalTrials.gov NCT06388642). Pharmacokinetic data describe the drug's concentration over time and help inform dosing decisions. Understanding pharmacokinetics in the approved EPP population is relevant to optimising the implant regimen and supporting any label updates.
- Efficacy benchmarks in this setting
- In the pivotal trials that supported the EMA approval granted in December 2014, afamelanotide-treated EPP patients showed statistically significant increases in time spent in sunlight without pain compared with placebo (per EMA European Public Assessment Report for SCENESSE). The FDA approved SCENESSE in October 2019 on the basis of similar efficacy data (per FDA approval announcement, October 2019). No other pharmacological therapy for EPP had received FDA or EMA approval prior to SCENESSE, so direct head-to-head comparisons with other approved agents in this setting are not available. Data from the pharmacokinetics study (NCT06388642) are not designed to assess efficacy and are not statistically comparable to the pivotal registration trial results.